Amelioration of nebivolol on renal interstitial fibrosis in UUO rats based on proteomic analysis

doi:10.12092/j.issn.1009-2501.2022.07.002

Abstract

Abstract: AIM: To explore the effect and mechanism of nebivolol on renal interstitial fibrosis(RIF) in unilateral ureteral obstruction (UUO) model through TMT proteomics. METHODS: SD rats were divided into Sham group, UUO group, Neb group(UUO rats treated with nebivolol 10 mg·kg-1·d-1, i.g.). Left kidney was collected from rat on 7th, 14th and 21th day after modeling. HE staining was used to observe renal structure and Masson's staining was used to examine RIF. Proteomic and bioinformatics were conducted to screen and analysis the differential expressed proteins contrary regulated between UUO/Sham and Neb/UUO 21d after obstruction. Western blot were used to confirm protein expressions. RESULTS: Compared with Sham group, RIF in UUO rats aggravated gradually. Administration of nebivolol for 21 d ameliorated RIF in UUO rats. A total of 179 differential expressed proteins contrary regulated were identified shared between UUO/Sham and Neb/UUO groups. KEGG enrichment analysis and PPI showed that these differential expressed proteins were mainly involved in spliceosome pathway. Results of Western blot for Rbm8a, Srsf9 and Sart1 were in line with the results of proteomics. CONCLUSION: Spliceosome may play key role in the amelioration of nebivolol on RIF in UUO rats.

Key words: nebivolol, renal interstitial fibrosis, unilateral ureteral obstruction, proteomics

CLC Number:

R965.2

WU Lijun, Li Xin, CUI Lijuan, LI Xinxin, WANG Yan. Amelioration of nebivolol on renal interstitial fibrosis in UUO rats based on proteomic analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 729-738.

References 24

[1]	Hill N, Fatoba S, Oke J, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis [J]. PloS one，2016，11(7)：e0158765.
[2]	Wang Y, Niu M, Yin S, et al. Nephroprotective effects of nebivolol in 2K1C rats through regulation of the kidney ROS-ADMA-NO pathway [J]. PHARMACOL REP，2018，70(5)：917-929.
[3]	Wang Y, An W, Zhang F, et al. Nebivolol ameliorated kidney damage in Zucker diabetic fatty rats by regulation of oxidative stress/NO pathway: Comparison with captopril [J]. CLIN EXP PHARMACOL P，2018，45(11)：1135-1148.
[4]	Pires?MJ,??Rodríguez-Pe?a?AB,??Arévalo?M,??et al. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction[J]. J Hypertens, 2007, 25(12):2486-2496.
[5]	Hewedy W, Mostafa D. Nebivolol suppresses asymmetric dimethylarginine and attenuates cyclosporine-induced nephrotoxicity and endothelial dysfunction in rats [J]. PHARMACOL REP，2016，68(6)：1319-1325.
[6]	Hayden?MR,??Habibi?J,??Whaley-Connell?A, et al.?Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats [J]. Am J Nephrol，2010，31(3)：262-272.
[7]	Nogueira A, Pires MJ, Oliveira PA. Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies [J]. In Vivo，2017，31(1)：1-22.
[8]	Song?J,??Liu?J,??Luo?J,??et al. A modified relief of unilateral ureteral obstruction model [J]. Ren Fail，2019，41(1)：497-506.
[9]	Jurica?MS,??Moore?M. Pre-mRNA splicing: awash in a sea of proteins [J]. Mol Cell，2003，12(1)：5-14.
[10]	Wahl?MC,??Will?CL,??Lührmann?R. Lührmann. The spliceosome: design principles of a dynamic RNP machine [J]. Cell，2009，136(4)：701-718.
[11]	Wally?V, Murauer?EM, Bauer?JW. Spliceosome-mediated trans-splicing: the therapeutic cut and paste [J]. J Invest Dermatol，2012，132(8)：1959-1966.
[12]	Wang?J,??Wang?Q,??Zhang?H,??et al. Moderate to Severe Marrow Fibrosis As a More Advanced Risk Factor for MDS and MDS-AML Patients With Excess of Blasts Receiving Allogeneic Hematopoietic Stem Cell Transplantation [J]. Transplant Cell Ther，2021，27(8)：666.e1- 666.e9
[13]	Midgley?AC,??Oltean?S,??Hascall?V,??et al. Nuclear hyaluronidase 2 drives alternative splicing of CD44 pre-mRNA to determine profibrotic or antifibrotic cell phenotype [J]. Sci Signal，2017，10(506)：eaao1822.
[14]	M?ller K, Wecker A, H?flmayer D, et al. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers [J]. Virchows Arch，2020，477(5)：625-636.
[15]	Thiele B, Doller A, K?hne T, et al. RNA-binding proteins heterogeneous nuclear ribonucleoprotein A1, E, and K are involved in post-transcriptional control of collagen I and III synthesis [J].CIRC RES，2004，95(11)：1058-1066.
[16]	左明堂，梁嵘，李永强. RBM8A与恶性肿瘤相关性研究进展[J]. 中华肿瘤防治杂志，2019，26(2)：132-136.
[17]	Ishigaki?Y,??Nakamura?Y,??Tatsuno?T,??et al. Depletion of RNA-binding protein?RBM8A(Y14) causes cell cycle deficiency and apoptosis in human cells [J]. Exp Biol Med (Maywood)，2013，238(8)：889-897.
[18]	Pan?T,??Zhou?Q,??Miao?K,??et al. Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis [J]. Theranostics，2021，11(3)：1192-1206.
[19]	Fu?Y,??Huang?B,??Shi?Z,??et al. SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing β-catenin biosynthesis [J]. EMBO Mol Med， 2013，5(5)：737-750.
[20]	刘艳，邵阿末，殷莹，等. SRSF9/SRp30c通过调控GRβ对胶质瘤细胞增殖和迁移的影响[J]. 中国病理生理杂志，2017，33(10)：1825-1830.
[21]	Song?Y,??He?S,??Ma?X,??et al. RBMX?contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1 [J]. Am J Cancer Res，2020，10(11)：3644-3665.
[22]	Mao?S,??Li?Y,??Lu?Z,??et al. PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing [J]. Cancer Med，2019，8(5)：2429-2441.
[23]	Zhu W, Zheng X, Jiang C, et al. Establishment and observation of a new and ideal reversible model of PUUO [J]. Renal failure，2017，39(1)：222-228.
[24]	Song J, Liu J, Luo J, et al. A modified relief of unilateral ureteral obstruction model [J]. Renal failure，2019，41(1)：497-506.